Clinical trials: Genomic
Malignant Neoplasm
Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.
This phase II trial studies how well ponatinib hydrochloride works in treating patients with cancer that has spread to other parts of the body (metastatic), has failed previous treatment (refractory), and has one of several…
- Trial name
- NCT02272998
- Testing
- ponatinib hydrochloride, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Sameek Roychowdhury
Melanoma (Skin)
Skin Health Online for Melanoma: Better Risk Assessment
This study will have two phases, with an added usability test after Phase I and before Phase 2. Phase 1: Cognitive Interviews of materials in Spanish. Phase 2: Personalized Genomic Testing for Skin Cancer (PGT-SC).
- Trial name
- SOMBRA (NCT03130569)
- Testing
- Web-based Module Group
- Where
- United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- University of New Mexico
Cluster Detection
CLUSTER Trial for Outbreak Detection and Response
Despite the critical importance of identifying hospital-associated outbreaks as early as possible in order to limit their spread, there are currently no standardized methods for cluster detection.
- Trial name
- CLUSTER (NCT04053075)
- Testing
- Routine cluster detection, Enhanced cluster detection
- Where
- 82 sites in United States
- Volunteers
- 2,905,455 people
- Sponsor
- Harvard Pilgrim Health Care
Pneumonia, Aging
Genomics and Epigenomics of the Elderly Response to Pneumococcal Vaccines
This is a prospective, single-site, randomized, then open-label study designed to develop a detailed transcriptional and epigenetic profile of the immune response to pneumococcal vaccination with conjugated and non-conjugated…
- Trial name
- NCT03104075
- Testing
- Pneumococcal 13valent Conj Vaccine Diphtheria CRM197 Protein, Pneumococcal Vaccine Polyvalent
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- The Jackson Laboratory
Chronic Kidney Disease, Hypertension
Genetic Testing to Understand and Address Renal Disease Disparities Across the United States
GUARDD-US is a prospective, multicenter, unblinded, two arm randomized pragmatic clinical trial. Participants will be randomized in a 1:1 ratio to immediate APOL1 gene testing and return of results (ROR) to participant and…
- Trial name
- GUARDD-US (NCT04191824)
- Testing
- Timing of return of results
- Where
- 14 sites in United States
- Volunteers
- 6,789 people
- Sponsor
- Duke University
Breast Carcinoma, Colorectal Carcinoma
HOPE-Genomics Intervention for the Improvement of Cancer Patient Knowledge of Genomics
This clinical trial studies the effectiveness of a web-based cancer education tool called Helping Oncology Patients Explore Genomics (HOPE-Genomics) in improving patient knowledge of personal genomic testing results and cancer…
- Conditions
- Breast Carcinoma, Colorectal Carcinoma, Lung Carcinoma, Malignant Solid Neoplasm
- Trial name
- NCT04905082
- Testing
- Best Practice, Educational Intervention, Genomic Profile
- Where
- United States
- Volunteers
- 465 people
- Sponsor
- City of Hope Medical Center
Malignant Solid Neoplasm, Recurrent Adrenal Gland Pheochromocytoma
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
This phase II pediatric MATCH trial studies how well tipifarnib works in treating patients with solid tumors that have recurred or spread to other places in the body (advanced), lymphoma, or histiocytic disorders, that have a…
- Conditions
- Malignant Solid Neoplasm, Recurrent Adrenal Gland Pheochromocytoma, Recurrent Ectomesenchymoma, Recurrent Ependymoma
- Trial name
- NCT04284774
- Testing
- Tipifarnib
- Where
- 172 sites in United States, Puerto Rico
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Epilepsy; Seizure, Neuromuscular Diseases
North Carolina Genomic Evaluation by Next-generation Exome Sequencing, 2
The "North Carolina Clinical Genomic Evaluation by Next-gen Exome Sequencing, 2 (NCGENES 2)" study is part of a larger consortium project investigating the clinical utility, or net benefit of an intervention on patient and family…
- Conditions
- Epilepsy; Seizure, Neuromuscular Diseases, Brain Malformation, Intellectual Disability
- Trial name
- NCGENES2 (NCT03548779)
- Testing
- Pre-visit prep, usual care + exome seq
- Where
- 3 sites in United States
- Volunteers
- 548 people
- Sponsor
- University of North Carolina, Chapel Hill
Cancer of Unknown Primary Site
A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site
This study will compare the efficacy and safety of molecularly-guided therapy versus standard platinum-containing chemotherapy in participants with poor-prognosis cancer of unknown primary site (CUP; non-specific subset) who have…
- Trial name
- CUPISCO (NCT03498521)
- Testing
- Alectinib, Vismodegib, Ipatasertib
- Where
- 125 sites in Australia, Austria and 31 more
- Volunteers
- 529 people
- Sponsor
- Hoffmann-La Roche
Carcinoma, Non-Small-Cell Lung
Adjuvant Cisplatin With Either Genomic-Guided Vinorelbine or Pemetrexed for Early Stage Non-Small-Cell Lung Cancer
This study assigned subjects to either cisplatin/vinorelbine or cisplatin/pemetrexed chemotherapy using a genomic based expression profile to determine chemotherapy sensitivity in completely resected early stage non-squamous…
- Trial name
- TOP0703 (NCT00545948)
- Testing
- Vinorelbine followed by Cisplatin, Pemetrexed followed by Cisplatin
- Where
- 13 sites in United States
- Volunteers
- 31 people
- Sponsor
- Duke University
Advanced Unresectable or Metastatic Solid Malignancy
A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response
This is a Phase II, multicenter, non-randomized, open-label, multi-arm study designed to evaluate the safety and efficacy of targeted therapies as single agents or in rational, specified combinations in participants with advanced…
- Trial name
- MyTACTIC (NCT04632992)
- Testing
- Entrectinib, Inavolisib, Alectinib
- Where
- 38 sites in United States
- Volunteers
- 252 people
- Sponsor
- Genentech, Inc.
Actinic Keratosis
Genomic Markers Before and After Treatment of Actinic Keratosis With Imiquimod 3.75% Cream
The study team had plans to treat approximately 30 subjects. Each subject that had qualified had at least 4-8 visible AKs on the face and/or scalp.
- Trial name
- NCT03914417
- Testing
- Imiquimod 3.75% Cream
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Stage II Breast Cancer, Stage IIIA Breast Cancer
Trastuzumab and Pertuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer
This phase II trial studies how well trastuzumab and pertuzumab or bevacizumab with combination chemotherapy works in treating patients with stage II-III breast cancer.
- Conditions
- Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
- Trial name
- NCT01959490
- Testing
- trastuzumab, Pertuzumab, docetaxel
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Case Comprehensive Cancer Center
Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma
Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma
This phase II trial investigates the effect of olaparib in treating patients with castration resistant prostate adenocarcinoma. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT04951492
- Testing
- Olaparib
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Washington
Genetic Diseases, Genetic Syndrome
Perinatal Precision Medicine
This study will seek to determine if rapid genomic sequencing improves outcomes for acutely ill infants. The investigator will enroll up to 1,000 acutely ill infants in a prospective, randomized, blinded study to either rapid…
- Conditions
- Genetic Diseases, Genetic Syndrome, Mendelian Disorders
- Trial name
- NSIGHT2 (NCT03211039)
- Testing
- Genomic sequencing and molecular diagnostic results, if any.
- Where
- United States
- Volunteers
- 213 people
- Sponsor
- Rady Pediatric Genomics & Systems Medicine Institute
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Study of Pembrolizumab in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine: Integration of Molecular Subtypes Through Integrative Genomic Analysis
This is a single-arm, single-center, open-label trial of pembrolizumab (MK-3475) in subjects with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma who have progressed after failure of any combination…
- Trial name
- NCT02589496
- Testing
- pembrolizumab
- Where
- South Korea
- Volunteers
- 80 people
- Sponsor
- Samsung Medical Center
Ann Arbor Stage I Small Lymphocytic Lymphoma, Ann Arbor Stage II Small Lymphocytic Lymphoma
Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
This phase II trial studies the effect of lenalidomide and vaccine in treating patients with early-stage asymptomatic chronic lymphocytic leukemia or small lymphocytic lymphoma.
- Conditions
- Ann Arbor Stage I Small Lymphocytic Lymphoma, Ann Arbor Stage II Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia With Unmutated Immunoglobulin Heavy Chain Variable-Region Gene
- Trial name
- NCT01351896
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- National Cancer Institute (NCI)
Coronary Artery Disease, Mild Cognitive Impairment
Genomic Outcomes of Metformin
Medical scientists have found that people with diabetes who take the drug Metformin have less age-related disease than those taking other treatments and researchers believe it may prevent numerous diseases and conditions that…
- Conditions
- Coronary Artery Disease, Mild Cognitive Impairment, Obesity, Abdominal, Hypertension
- Trial name
- GOMET (NCT02986659)
- Testing
- Metformin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Wake Forest University Health Sciences
Seemingly Healthy, Genetic Predisposition to Disease
Return of Genomic Results and Aggregate Penetrance in Population-Based Cohorts
The PopSeq Project is a prospective cohort study that will develop and implement a genomic return of results (gRoR) process in the Framingham Heart Study (FHS) and Jackson Heart Study (JHS) cohorts and explore associated medical…
- Trial name
- PopSeq (NCT04196374)
- Testing
- Genomic Sequencing
- Where
- 2 sites in United States
- Volunteers
- 7,603 people
- Sponsor
- Brigham and Women's Hospital
Intellectual Disability, Autism
Enhancing Genomic Laboratory Reports to Enhance Communication and Empower Patients
Current lab reports are designed to communicate results from the laboratory to the provider; they are not designed to be accessible to patients.
- Conditions
- Intellectual Disability, Autism, Multiple Congenital Anomalies
- Trial name
- NCT02504502
- Testing
- enhanced genomic report
- Volunteers
- 52 people
- Sponsor
- Geisinger Clinic